Deutsche Bank Adjusts AbbVie Price Target to $180 From $175, Maintains Hold Rating
AbbVie Analyst Ratings
Argus Research Upgrades AbbVie(ABBV.US) to Buy Rating
Argus Upgrades AbbVie to Buy From Hold, Price Target Is $220
Barclays Maintains AbbVie(ABBV.US) With Buy Rating, Maintains Target Price $212
AbbVie Price Target Raised to $226.00/Share From $215.00 by Citigroup
AbbVie Is Maintained at Buy by Citigroup
UBS Adjusts Price Target on AbbVie to $200 From $195, Maintains Neutral Rating
Cantor Fitzgerald Maintains AbbVie(ABBV.US) With Buy Rating, Raises Target Price to $240
A Quick Look at Today's Ratings for AbbVie(ABBV.US), With a Forecast Between $205 to $240
AbbVie Analyst Ratings
Morgan Stanley Maintains Overweight on AbbVie, Raises Price Target to $231
Evercore ISI Adjusts Price Target on AbbVie to $204 From $192
Leerink Partners Maintains AbbVie(ABBV.US) With Hold Rating
AbbVie Is Maintained at Buy by Citigroup
AbbVie Analyst Ratings
Piper Sandler Maintains AbbVie(ABBV.US) With Buy Rating, Maintains Target Price $209
AbbVie (ABBV) Gets a Buy From Piper Sandler
Leerink Partners Maintains AbbVie(ABBV.US) With Hold Rating, Announces Target Price $206
AbbVie: Balanced Outlook Amid EPS Adjustments and Pipeline Uncertainties Warrants Hold Rating